arrow
C

C. Benvenuti

humanitas cancer center
H指数:15
被引数:968

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review

曲妥珠单抗德鲁替康在HER2阳性转移性乳腺癌合并严重肝功能不全中的应用:病例报告及文献综述

2026-09-140
OA
[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

^{18}F-FDG PET/CT作为早期乳腺癌新辅助治疗中评估疗效的生物标志物:在新兴的增减量策略背景下,它能否成为变革性因素?

2025-12-010
OAAI
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

从静脉到皮下注射帕妥珠单抗/曲妥珠单抗治疗乳腺癌:转换的临床和药物经济学驱动因素与障碍

2025-12-010
PRE
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists

纳入放射组学MRI模型用于早期乳腺癌患者新辅助系统性治疗前手术前反应评估:乳腺肿瘤学家和放射科医师的协作见解

2025-06-010
PRE
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review

揭示细胞周期蛋白依赖性激酶4和6抑制剂在激素受体阳性/人表皮生长因子阴性晚期乳腺癌中进展的潜力-临床综述

2024-11-301
OAAI
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial)

通过疼痛神经科学教育,早期三阴性乳腺癌患者的授权,疼痛控制和生活质量改善: 一项前瞻性队列试点研究方案 (EMPOWER试验)

2024-07-012
OAAI
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023-04-1715
OAAI
HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
2023-03-013
PRE